211 related articles for article (PubMed ID: 32474034)
1. Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient.
Sagnelli C; Gentile V; Tirri R; Macera M; Cappabianca S; Ciccia F; Coppola N;
J Infect; 2020 Dec; 81(6):979-997. PubMed ID: 32474034
[No Abstract] [Full Text] [Related]
2. Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.
Georgiev T
Rheumatol Int; 2020 May; 40(5):825-826. PubMed ID: 32232552
[No Abstract] [Full Text] [Related]
3. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD.
Hasseli R; Mueller-Ladner U; Schmeiser T; Hoyer BF; Krause A; Lorenz HM; Regierer AC; Richter JG; Strangfeld A; Voll RE; Pfeil A; Schulze-Koops H; Specker C
RMD Open; 2020 Sep; 6(2):. PubMed ID: 32878994
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM;
Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857
[No Abstract] [Full Text] [Related]
5. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
[TBL] [Abstract][Full Text] [Related]
6. Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Nuño L; Novella Navarro M; Bonilla G; Franco-Gómez K; Aguado P; Peiteado D; Monjo I; Tornero C; Villalba A; Miranda-Carus ME; De Miguel E; Bogas P; Castilla-Plaza A; Bernad-Pineda M; García-Lorenzo E; Rodríguez-Araya T; Balsa A
Ann Rheum Dis; 2020 Dec; 79(12):1659-1661. PubMed ID: 32606046
[No Abstract] [Full Text] [Related]
7. Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.
Migkos MP; Kaltsonoudis E; Pelechas E; Drossou V; Karagianni PG; Kavvadias A; Voulgari PV; Drosos AA
Rheumatol Int; 2021 May; 41(5):903-909. PubMed ID: 33655421
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Pablos JL; Galindo M; Carmona L; Lledó A; Retuerto M; Blanco R; Gonzalez-Gay MA; Martinez-Lopez D; Castrejón I; Alvaro-Gracia JM; Fernández Fernández D; Mera-Varela A; Manrique-Arija S; Mena Vázquez N; Fernandez-Nebro A; ;
Ann Rheum Dis; 2020 Dec; 79(12):1544-1549. PubMed ID: 32796045
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy.
Ceribelli A; Motta F; De Santis M; Ansari AA; Ridgway WM; Gershwin ME; Selmi C
J Autoimmun; 2020 May; 109():102442. PubMed ID: 32253068
[TBL] [Abstract][Full Text] [Related]
10. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
[TBL] [Abstract][Full Text] [Related]
11. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Cai S; Sun W; Li M; Dong L
Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
[TBL] [Abstract][Full Text] [Related]
12. How to manage rheumatic patients during the coronavirus pandemic.
Parisi S; Ditto MC; Finucci A; Fusaro E
Panminerva Med; 2020 Sep; 62(3):176-177. PubMed ID: 32343511
[No Abstract] [Full Text] [Related]
13. Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology.
Saldarriaga Rivera LM; Fernández Ávila D; Bautista Molano W; Jaramillo Arroyave D; Bautista Ramírez AJ; Díaz Maldonado A; Hernán Izquierdo J; Jáuregui E; Latorre Muñoz MC; Restrepo JP; Segura Charry JS
Reumatol Clin (Engl Ed); 2020; 16(6):437-446. PubMed ID: 32800760
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
[TBL] [Abstract][Full Text] [Related]
15. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 infection among patients with systemic autoimmune diseases.
Emmi G; Bettiol A; Mattioli I; Silvestri E; Di Scala G; Urban ML; Vaglio A; Prisco D
Autoimmun Rev; 2020 Jul; 19(7):102575. PubMed ID: 32376395
[TBL] [Abstract][Full Text] [Related]
17. Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19.
Gazzaruso C; Carlo Stella N; Mariani G; Tamburlini A; Garini P; Freddi E; Ravetto C; Coppola A; Gallotti P
Clin Rheumatol; 2020 Aug; 39(8):2475-2477. PubMed ID: 32548723
[No Abstract] [Full Text] [Related]
18. COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.
Ouédraogo DD; Tiendrébéogo WJS; Kaboré F; Ntsiba H
Clin Rheumatol; 2020 Jul; 39(7):2069-2075. PubMed ID: 32472461
[TBL] [Abstract][Full Text] [Related]
19. Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Santos CS; Morales CM; Álvarez ED; Castro CÁ; Robles AL; Sandoval TP
Clin Rheumatol; 2020 Sep; 39(9):2789-2796. PubMed ID: 32720259
[TBL] [Abstract][Full Text] [Related]
20. SARS CoV-2 infection among patients using immunomodulatory therapies.
Winthrop KL; Brunton AE; Beekmann S; Polgreen P; Baddley J; Saag KG; Calabrese C; Calabrese L; Robinson PC; Wallace ZS; Curtis JR;
Ann Rheum Dis; 2021 Feb; 80(2):269-271. PubMed ID: 32759259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
